Safety and efficacy of percutaneous femoral artery access followed by Mynx closure in cerebral neurovascular procedures: a single center analysis

Abstract

The Mynx device is safe and effective for cerebral neurovascular procedures. However, specific patient populations may warrant particular attention and thorough consideration of risks and benefits prior to employing the Mynx device for femoral arteriotomy closure.

Incidence of delayed angiographic femoral artery complications using the EXOSEAL vascular closure device

“…The 90.7% success rate for femoral arterial puncture closure and 1.6% minor complication rate using the EXOSEAL VCD in our study is congruent with prior reports of the device’s efficacy and complication rates, 32–34 and is in line with other plug-mediated closure devices. 35 No patients in our study cohort experienced symptomatic leg ischemia, and seven out of 102 patients (6.86%) with repeat angiograms were observed to have minor vessel stenosis.…”

Successful Use of the MYNXGRIP Closure Device during Repeated Transbrachial Percutaneous Peripheral Intervention

“…Nevertheless, some authors report a relevant rate of intraluminal migration of the sealant material (18%) or formation of false aneurysm (11%) [ 13 – 15 ]. Grandhi et al reported in their analysis on the use of the MYNX device in transfemoral cerebrovascular interventions an association of lower body-mass index and complication rate [ 16 ]. Whether the safety and efficacy of the device are comparable to other systems still remains unclear so far [ 17 – 19 ].…”

Safety and efficacy of combined micropuncture and shallow angle femoral artery access for neurovascular angiography

“…Patients with dense vascular calcifications or more importantly, morbid obesity, were selected for standard arterial access rather than AXERA 2 use. The known increased risk of bleeding complications associated with obesity (21) may in part explain the considerably higher incidence of local hematoma in the standard access group. Excluding this higher risk population from the AXERA 2 subset prohibits extrapolating primacy from these data.…”